NIH-funded study reports advance in blood-based detection of ptau181, a biomarker of Alzheimer’s disease

The National Institute of Health debuted a press release on March 2 following the study’s findings being published in Nature Medicine the same day. The study reported an advance in the development of a blood test to detect pathological Alzheimer’s disease for people displaying dementia symptoms. The study was led by researchers at the University of California, San Francisco and sponsored by Eli Lilly. Their analysis demonstrated that the ptau181 biomarker in plasma could be successful in differentiating healthy participants from those with Alzheimer’s pathology and frontotemporal lobar degeneration (FTLD). This finding is particularly important because a blood test will allow for more accurate, and less costly, diagnoses of Alzheimer’s disease, which will ultimately help the ongoing research for a cure or intervention.
To read more about this discovery, find the complete press release here.